NanoString Technologies Inc
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2012 | $15 M | No. 4 | $10 to $50 million | equity | SEC | |
| Nov 2011 | $20 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Jun 2011 | $3 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Jun 2009 | $14 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
NanoString Technologies Inc chose not to state its revenue in its newest notice of a funding round (Dec 2012).
SEC Form D · Dec 2012
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2012
That is all the official record says: NanoString Technologies Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Clarus Lifesciences II, L.P. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Clarus Ventures II GP, L.P. | Venture capital | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Clarus Ventures II, LLC | Venture capital | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Draper Associates L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Draper Associates Riskmasters Fund II, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Draper Associates Riskmasters Fund, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Draper Fisher Jurvetson Fund VII, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Draper Fisher Jurvetson Partners VII, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mary Tedd Allen | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2013) | SEC Form 3 |
| Ovp Venture Partners VII LP | Venture capital | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Ovp Venture Partners VI LP | Venture capital | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Ovp VI Entrepreneurs Fund LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Ovp VII Entrepreneurs Fund LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 15 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| James Bradley Johnson | Executive officer | Dec 2012 |
| Robert Bradley Gray | Executive officer | Dec 2012 |
| Wayne Bradley Burns | Executive officer | Dec 2012 |
| Wayne Burns | Executive officer | Jun 2009 |
| Charles Bradley Waite | Director | Dec 2012 |
| Finny Bradley Kuruvilla | Director | Dec 2012 |
| Gregory Bradley Norden | Director | Dec 2012 |
| Jennifer Bradley Fonstad | Director | Dec 2012 |
| Nicholas Bradley Galakatos | Director | Dec 2012 |
| Robert Bradley Gray | Director | Dec 2012 |
| William D. Young | Director | Dec 2012 |
| Charles Scott Waite | Director | Nov 2011 |
| Finny D. Kuruvilla | Director | Nov 2011 |
| Jennifer Scott Fonstad | Director | Nov 2011 |
| Nicholas Scott Galakatos | Director | Nov 2011 |
| H. Perry Fell | Director | Jun 2011 |
| Charles Waite | Director | Jun 2009 |
| Jennifer Fonstad | Director | Jun 2009 |
| Nicholas Galaktos | Director | Jun 2009 |
| Perry Fell | Director | Jun 2009 |
About
Biotechnology company.